APO Research
Talk to an analyst

APO RESEARCH · REPORT

Novel Oral AntiCoagulants (NOAC)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Novel Oral AntiCoagulants (NOAC) Market Analysis and Forecast 2026-2032

26 December 2025202 pages

Choose your research edition.

Industry ResearchNovel Oral AntiCoagulants (NOAC) Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Novel Oral AntiCoagulants (NOAC) Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Novel Oral AntiCoagulants (NOAC) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Novel Oral AntiCoagulants (NOAC) Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Novel Oral AntiCoagulants (NOAC) Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Novel Oral AntiCoagulants (NOAC) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Novel Oral AntiCoagulants (NOAC) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Novel Oral AntiCoagulants (NOAC) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Novel Oral AntiCoagulants (NOAC) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Novel Oral AntiCoagulants (NOAC) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Novel Oral AntiCoagulants (NOAC) include Armatheon, Aspen, Boehringer Ingelheim, Bristol-Myers Squibb, Cellceutix, Cosmo Pharmaceuticals, CSL Behring, Daiichi Sankyo and Marathon Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Novel Oral AntiCoagulants (NOAC), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Novel Oral AntiCoagulants (NOAC), also provides the sales of main regions and countries. Of the upcoming market potential for Novel Oral AntiCoagulants (NOAC), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Novel Oral AntiCoagulants (NOAC) sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Novel Oral AntiCoagulants (NOAC) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Novel Oral AntiCoagulants (NOAC) sales, projected growth trends, production technology, application and end-user industry.

Novel Oral AntiCoagulants (NOAC) Segment by Company

Armatheon

Aspen

Boehringer Ingelheim

Bristol-Myers Squibb

Cellceutix

Cosmo Pharmaceuticals

CSL Behring

Daiichi Sankyo

Marathon Pharmaceuticals

Ockham Biotech

Perosphere

AstraZeneca

Bayer

GSK

Johnson & Johnson

Sanofi

Eisai

Novel Oral AntiCoagulants (NOAC) Segment by Type

Direct Thrombin Inhibitors

Direct Factor Xa Inhibitors

Novel Oral AntiCoagulants (NOAC) Segment by Application

Hemodialysis

Deep Vein Thrombosis (DVT)

Acute Coronary Syndrome

Pulmonary Embolism

Others

Novel Oral AntiCoagulants (NOAC) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Novel Oral AntiCoagulants (NOAC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Novel Oral AntiCoagulants (NOAC) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Novel Oral AntiCoagulants (NOAC).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Novel Oral AntiCoagulants (NOAC) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Novel Oral AntiCoagulants (NOAC) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Novel Oral AntiCoagulants (NOAC) sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Direct Thrombin Inhibitors Major Manufacturers Table 3. Direct Factor Xa Inhibitors Major Manufacturers Table 4. Global Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hemodialysis Major Manufacturers Table 6. Deep Vein Thrombosis (DVT) Major Manufacturers Table 7. Acute Coronary Syndrome Major Manufacturers Table 8. Pulmonary Embolism Major Manufacturers Table 9. Others Major Manufacturers Table 10. Novel Oral AntiCoagulants (NOAC) Industry Trends Table 11. Novel Oral AntiCoagulants (NOAC) Industry Drivers Table 12. Novel Oral AntiCoagulants (NOAC) Industry Opportunities and Challenges Table 13. Novel Oral AntiCoagulants (NOAC) Industry Restraints Table 14. Global Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Novel Oral AntiCoagulants (NOAC) Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Novel Oral AntiCoagulants (NOAC) Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region (2021-2026) Table 18. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region (2027-2032) Table 19. Global Novel Oral AntiCoagulants (NOAC) Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 20. Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2021-2026) & (W Units) Table 21. Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2027-2032) & (W Units) Table 22. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region (2021-2026) Table 23. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region (2027-2032) Table 24. Global Novel Oral AntiCoagulants (NOAC) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Novel Oral AntiCoagulants (NOAC) Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Manufacturers (2021-2026) Table 28. Global Novel Oral AntiCoagulants (NOAC) Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Novel Oral AntiCoagulants (NOAC) Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Novel Oral AntiCoagulants (NOAC) Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Novel Oral AntiCoagulants (NOAC) Manufacturers, Product Type & Application Table 32. Global Novel Oral AntiCoagulants (NOAC) Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Novel Oral AntiCoagulants (NOAC) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Novel Oral AntiCoagulants (NOAC) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type (2021-2026) Table 39. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type (2027-2032) Table 40. Global Novel Oral AntiCoagulants (NOAC) Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 41. Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (W Units) Table 42. Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2027-2032) & (W Units) Table 43. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2021-2026) Table 44. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2027-2032) Table 45. Global Novel Oral AntiCoagulants (NOAC) Price by Type (2021-2026) & (US$/Unit) Table 46. Global Novel Oral AntiCoagulants (NOAC) Price by Type (2027-2032) & (US$/Unit) Table 47. Global Novel Oral AntiCoagulants (NOAC) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Novel Oral AntiCoagulants (NOAC) Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application (2021-2026) Table 51. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application (2027-2032) Table 52. Global Novel Oral AntiCoagulants (NOAC) Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 53. Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (W Units) Table 54. Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2027-2032) & (W Units) Table 55. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2021-2026) Table 56. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2027-2032) Table 57. Global Novel Oral AntiCoagulants (NOAC) Price by Application (2021-2026) & (US$/Unit) Table 58. Global Novel Oral AntiCoagulants (NOAC) Price by Application (2027-2032) & (US$/Unit) Table 59. Armatheon Company Information Table 60. Armatheon Business Overview Table 61. Armatheon Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Armatheon Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 63. Armatheon Recent Development Table 64. Aspen Company Information Table 65. Aspen Business Overview Table 66. Aspen Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Aspen Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 68. Aspen Recent Development Table 69. Boehringer Ingelheim Company Information Table 70. Boehringer Ingelheim Business Overview Table 71. Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 73. Boehringer Ingelheim Recent Development Table 74. Bristol-Myers Squibb Company Information Table 75. Bristol-Myers Squibb Business Overview Table 76. Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 78. Bristol-Myers Squibb Recent Development Table 79. Cellceutix Company Information Table 80. Cellceutix Business Overview Table 81. Cellceutix Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Cellceutix Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 83. Cellceutix Recent Development Table 84. Cosmo Pharmaceuticals Company Information Table 85. Cosmo Pharmaceuticals Business Overview Table 86. Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 88. Cosmo Pharmaceuticals Recent Development Table 89. CSL Behring Company Information Table 90. CSL Behring Business Overview Table 91. CSL Behring Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. CSL Behring Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 93. CSL Behring Recent Development Table 94. Daiichi Sankyo Company Information Table 95. Daiichi Sankyo Business Overview Table 96. Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 98. Daiichi Sankyo Recent Development Table 99. Marathon Pharmaceuticals Company Information Table 100. Marathon Pharmaceuticals Business Overview Table 101. Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 103. Marathon Pharmaceuticals Recent Development Table 104. Ockham Biotech Company Information Table 105. Ockham Biotech Business Overview Table 106. Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 108. Ockham Biotech Recent Development Table 109. Perosphere Company Information Table 110. Perosphere Business Overview Table 111. Perosphere Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Perosphere Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 113. Perosphere Recent Development Table 114. AstraZeneca Company Information Table 115. AstraZeneca Business Overview Table 116. AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. AstraZeneca Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 118. AstraZeneca Recent Development Table 119. Bayer Company Information Table 120. Bayer Business Overview Table 121. Bayer Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Bayer Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 123. Bayer Recent Development Table 124. GSK Company Information Table 125. GSK Business Overview Table 126. GSK Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. GSK Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 128. GSK Recent Development Table 129. Johnson & Johnson Company Information Table 130. Johnson & Johnson Business Overview Table 131. Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 133. Johnson & Johnson Recent Development Table 134. Sanofi Company Information Table 135. Sanofi Business Overview Table 136. Sanofi Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Sanofi Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 138. Sanofi Recent Development Table 139. Eisai Company Information Table 140. Eisai Business Overview Table 141. Eisai Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Eisai Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 143. Eisai Recent Development Table 144. North America Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021-2026) & (US$ Million) Table 145. North America Novel Oral AntiCoagulants (NOAC) Revenue by Type (2027-2032) & (US$ Million) Table 146. North America Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (W Units) Table 147. North America Novel Oral AntiCoagulants (NOAC) Sales by Type (2027-2032) & (W Units) Table 148. North America Novel Oral AntiCoagulants (NOAC) Sales Price by Type (2021-2026) & (US$/Unit) Table 149. North America Novel Oral AntiCoagulants (NOAC) Sales Price by Type (2027-2032) & (US$/Unit) Table 150. North America Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021-2026) & (US$ Million) Table 151. North America Novel Oral AntiCoagulants (NOAC) Revenue by Application (2027-2032) & (US$ Million) Table 152. North America Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (W Units) Table 153. North America Novel Oral AntiCoagulants (NOAC) Sales by Application (2027-2032) & (W Units) Table 154. North America Novel Oral AntiCoagulants (NOAC) Sales Price by Application (2021-2026) & (US$/Unit) Table 155. North America Novel Oral AntiCoagulants (NOAC) Sales Price by Application (2027-2032) & (US$/Unit) Table 156. North America Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. North America Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 158. North America Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 159. North America Novel Oral AntiCoagulants (NOAC) Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 160. North America Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026) & (W Units) Table 161. North America Novel Oral AntiCoagulants (NOAC) Sales by Country (2027-2032) & (W Units) Table 162. North America Novel Oral AntiCoagulants (NOAC) Sales Price by Country (2021-2026) & (US$/Unit) Table 163. North America Novel Oral AntiCoagulants (NOAC) Sales Price by Country (2027-2032) & (US$/Unit) Table 164. United States Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 165. Canada Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 166. Mexico Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 167. Europe Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021-2026) & (US$ Million) Table 168. Europe Novel Oral AntiCoagulants (NOAC) Revenue by Type (2027-2032) & (US$ Million) Table 169. Europe Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (W Units) Table 170. Europe Novel Oral AntiCoagulants (NOAC) Sales by Type (2027-2032) & (W Units) Table 171. Europe Novel Oral AntiCoagulants (NOAC) Sales Price by Type (2021-2026) & (US$/Unit) Table 172. Europe Novel Oral AntiCoagulants (NOAC) Sales Price by Type (2027-2032) & (US$/Unit) Table 173. Europe Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021-2026) & (US$ Million) Table 174. Europe Novel Oral AntiCoagulants (NOAC) Revenue by Application (2027-2032) & (US$ Million) Table 175. Europe Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (W Units) Table 176. Europe Novel Oral AntiCoagulants (NOAC) Sales by Application (2027-2032) & (W Units) Table 177. Europe Novel Oral AntiCoagulants (NOAC) Sales Price by Application (2021-2026) & (US$/Unit) Table 178. Europe Novel Oral AntiCoagulants (NOAC) Sales Price by Application (2027-2032) & (US$/Unit) Table 179. Europe Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 180. Europe Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 181. Europe Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 182. Europe Novel Oral AntiCoagulants (NOAC) Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 183. Europe Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026) & (W Units) Table 184. Europe Novel Oral AntiCoagulants (NOAC) Sales by Country (2027-2032) & (W Units) Table 185. Europe Novel Oral AntiCoagulants (NOAC) Sales Price by Country (2021-2026) & (US$/Unit) Table 186. Europe Novel Oral AntiCoagulants (NOAC) Sales Price by Country (2027-2032) & (US$/Unit) Table 187. Germany Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 188. France Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 189. U.K. Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 190. Italy Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 191. Russia Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 192. Spain Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 193. Netherlands Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 194. Switzerland Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 195. Sweden Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 196. Poland Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 197. China Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021-2026) & (US$ Million) Table 198. China Novel Oral AntiCoagulants (NOAC) Revenue by Type (2027-2032) & (US$ Million) Table 199. China Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (W Units) Table 200. China Novel Oral AntiCoagulants (NOAC) Sales by Type (2027-2032) & (W Units) Table 201. China Novel Oral AntiCoagulants (NOAC) Sales Price by Type (2021-2026) & (US$/Unit) Table 202. China Novel Oral AntiCoagulants (NOAC) Sales Price by Type (2027-2032) & (US$/Unit) Table 203. China Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021-2026) & (US$ Million) Table 204. China Novel Oral AntiCoagulants (NOAC) Revenue by Application (2027-2032) & (US$ Million) Table 205. China Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (W Units) Table 206. China Novel Oral AntiCoagulants (NOAC) Sales by Application (2027-2032) & (W Units) Table 207. China Novel Oral AntiCoagulants (NOAC) Sales Price by Application (2021-2026) & (US$/Unit) Table 208. China Novel Oral AntiCoagulants (NOAC) Sales Price by Application (2027-2032) & (US$/Unit) Table 209. Asia Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021-2026) & (US$ Million) Table 210. Asia Novel Oral AntiCoagulants (NOAC) Revenue by Type (2027-2032) & (US$ Million) Table 211. Asia Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (W Units) Table 212. Asia Novel Oral AntiCoagulants (NOAC) Sales by Type (2027-2032) & (W Units) Table 213. Asia Novel Oral AntiCoagulants (NOAC) Sales Price by Type (2021-2026) & (US$/Unit) Table 214. Asia Novel Oral AntiCoagulants (NOAC) Sales Price by Type (2027-2032) & (US$/Unit) Table 215. Asia Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021-2026) & (US$ Million) Table 216. Asia Novel Oral AntiCoagulants (NOAC) Revenue by Application (2027-2032) & (US$ Million) Table 217. Asia Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (W Units) Table 218. Asia Novel Oral AntiCoagulants (NOAC) Sales by Application (2027-2032) & (W Units) Table 219. Asia Novel Oral AntiCoagulants (NOAC) Sales Price by Application (2021-2026) & (US$/Unit) Table 220. Asia Novel Oral AntiCoagulants (NOAC) Sales Price by Application (2027-2032) & (US$/Unit) Table 221. Asia Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 222. Asia Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 223. Asia Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 224. Asia Novel Oral AntiCoagulants (NOAC) Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 225. Asia Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026) & (W Units) Table 226. Asia Novel Oral AntiCoagulants (NOAC) Sales by Country (2027-2032) & (W Units) Table 227. Asia Novel Oral AntiCoagulants (NOAC) Sales Price by Country (2021-2026) & (US$/Unit) Table 228. Asia Novel Oral AntiCoagulants (NOAC) Sales Price by Country (2027-2032) & (US$/Unit) Table 229. Japan Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 230. South Korea Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 231. India Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 232. Australia Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 233. Taiwan Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 234. Southeast Asia Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 235. SAMEA Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021-2026) & (US$ Million) Table 236. SAMEA Novel Oral AntiCoagulants (NOAC) Revenue by Type (2027-2032) & (US$ Million) Table 237. SAMEA Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (W Units) Table 238. SAMEA Novel Oral AntiCoagulants (NOAC) Sales by Type (2027-2032) & (W Units) Table 239. SAMEA Novel Oral AntiCoagulants (NOAC) Sales Price by Type (2021-2026) & (US$/Unit) Table 240. SAMEA Novel Oral AntiCoagulants (NOAC) Sales Price by Type (2027-2032) & (US$/Unit) Table 241. SAMEA Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021-2026) & (US$ Million) Table 242. SAMEA Novel Oral AntiCoagulants (NOAC) Revenue by Application (2027-2032) & (US$ Million) Table 243. SAMEA Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (W Units) Table 244. SAMEA Novel Oral AntiCoagulants (NOAC) Sales by Application (2027-2032) & (W Units) Table 245. SAMEA Novel Oral AntiCoagulants (NOAC) Sales Price by Application (2021-2026) & (US$/Unit) Table 246. SAMEA Novel Oral AntiCoagulants (NOAC) Sales Price by Application (2027-2032) & (US$/Unit) Table 247. SAMEA Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 248. SAMEA Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 249. SAMEA Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 250. SAMEA Novel Oral AntiCoagulants (NOAC) Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 251. SAMEA Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026) & (W Units) Table 252. SAMEA Novel Oral AntiCoagulants (NOAC) Sales by Country (2027-2032) & (W Units) Table 253. SAMEA Novel Oral AntiCoagulants (NOAC) Sales Price by Country (2021-2026) & (US$/Unit) Table 254. SAMEA Novel Oral AntiCoagulants (NOAC) Sales Price by Country (2027-2032) & (US$/Unit) Table 255. Brazil Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 256. Argentina Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 257. Chile Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 258. Colombia Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 259. Peru Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 260. Saudi Arabia Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 261. Israel Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 262. UAE Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 263. Turkey Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 264. Iran Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 265. Egypt Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Table 266. Key Raw Materials Table 267. Raw Materials Key Suppliers Table 268. Novel Oral AntiCoagulants (NOAC) Distributors List Table 269. Novel Oral AntiCoagulants (NOAC) Customers List Table 270. Research Programs/Design for This Report Table 271. Authors List of This Report Table 272. Secondary Sources Table 273. Primary Sources List of Figures Figure 1. Novel Oral AntiCoagulants (NOAC) Image Figure 2. Global Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Novel Oral AntiCoagulants (NOAC) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Direct Thrombin Inhibitors Image Figure 5. Direct Factor Xa Inhibitors Image Figure 6. Global Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Novel Oral AntiCoagulants (NOAC) Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hemodialysis Image Figure 9. Deep Vein Thrombosis (DVT) Image Figure 10. Acute Coronary Syndrome Image Figure 11. Pulmonary Embolism Image Figure 12. Others Image Figure 13. Global Novel Oral AntiCoagulants (NOAC) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Figure 15. Global Novel Oral AntiCoagulants (NOAC) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region (2021-2032) Figure 18. Global Novel Oral AntiCoagulants (NOAC) Sales (2021-2032) & (W Units) Figure 19. Global Novel Oral AntiCoagulants (NOAC) Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 20. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Novel Oral AntiCoagulants (NOAC) Sales YoY (2021-2032) & (W Units) Figure 22. Europe Novel Oral AntiCoagulants (NOAC) Sales YoY (2021-2032) & (W Units) Figure 23. China Novel Oral AntiCoagulants (NOAC) Sales YoY (2021-2032) & (W Units) Figure 24. Asia (Excluding China) Novel Oral AntiCoagulants (NOAC) Sales YoY (2021-2032) & (W Units) Figure 25. South America, Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales YoY (2021-2032) & (W Units) Figure 26. Global Novel Oral AntiCoagulants (NOAC) Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Novel Oral AntiCoagulants (NOAC) Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type (2021-2032) Figure 32. Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 33. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2021-2032) Figure 35. Global Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application (2021-2032) Figure 38. Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 39. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2021-2032) Figure 41. North America Novel Oral AntiCoagulants (NOAC) Revenue Share by Type (2021-2032) Figure 42. North America Novel Oral AntiCoagulants (NOAC) Sales Share by Type (2021-2032) Figure 43. North America Novel Oral AntiCoagulants (NOAC) Revenue Share by Application (2021-2032) Figure 44. North America Novel Oral AntiCoagulants (NOAC) Sales Share by Application (2021-2032) Figure 45. North America Novel Oral AntiCoagulants (NOAC) Revenue Share by Country (2021-2032) Figure 46. North America Novel Oral AntiCoagulants (NOAC) Sales Share by Country (2021-2032) Figure 47. Europe Novel Oral AntiCoagulants (NOAC) Revenue Share by Type (2021-2032) Figure 48. Europe Novel Oral AntiCoagulants (NOAC) Sales Share by Type (2021-2032) Figure 49. Europe Novel Oral AntiCoagulants (NOAC) Revenue Share by Application (2021-2032) Figure 50. Europe Novel Oral AntiCoagulants (NOAC) Sales Share by Application (2021-2032) Figure 51. Europe Novel Oral AntiCoagulants (NOAC) Revenue Share by Country (2021-2032) Figure 52. Europe Novel Oral AntiCoagulants (NOAC) Sales Share by Country (2021-2032) Figure 53. China Novel Oral AntiCoagulants (NOAC) Revenue Share by Type (2021-2032) Figure 54. China Novel Oral AntiCoagulants (NOAC) Sales Share by Type (2021-2032) Figure 55. China Novel Oral AntiCoagulants (NOAC) Revenue Share by Application (2021-2032) Figure 56. China Novel Oral AntiCoagulants (NOAC) Sales Share by Application (2021-2032) Figure 57. Asia Novel Oral AntiCoagulants (NOAC) Revenue Share by Type (2021-2032) Figure 58. Asia Novel Oral AntiCoagulants (NOAC) Sales Share by Type (2021-2032) Figure 59. Asia Novel Oral AntiCoagulants (NOAC) Revenue Share by Application (2021-2032) Figure 60. Asia Novel Oral AntiCoagulants (NOAC) Sales Share by Application (2021-2032) Figure 61. Asia Novel Oral AntiCoagulants (NOAC) Revenue Share by Country (2021-2032) Figure 62. Asia Novel Oral AntiCoagulants (NOAC) Sales Share by Country (2021-2032) Figure 63. SAMEA Novel Oral AntiCoagulants (NOAC) Revenue Share by Type (2021-2032) Figure 64. SAMEA Novel Oral AntiCoagulants (NOAC) Sales Share by Type (2021-2032) Figure 65. SAMEA Novel Oral AntiCoagulants (NOAC) Revenue Share by Application (2021-2032) Figure 66. SAMEA Novel Oral AntiCoagulants (NOAC) Sales Share by Application (2021-2032) Figure 67. SAMEA Novel Oral AntiCoagulants (NOAC) Revenue Share by Country (2021-2032) Figure 68. SAMEA Novel Oral AntiCoagulants (NOAC) Sales Share by Country (2021-2032) Figure 69. Novel Oral AntiCoagulants (NOAC) Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Novel Oral AntiCoagulants (NOAC) Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Direct Thrombin Inhibitors
  • Direct Factor Xa Inhibitors
Applications
  • Hemodialysis
  • Deep Vein Thrombosis (DVT)
  • Acute Coronary Syndrome
  • Pulmonary Embolism
  • Others
Companies covered
  • Armatheon
  • Aspen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cellceutix
  • Cosmo Pharmaceuticals
  • CSL Behring
  • Daiichi Sankyo
  • Marathon Pharmaceuticals
  • Ockham Biotech
  • Perosphere
  • AstraZeneca
  • Bayer
  • GSK
  • Johnson & Johnson
  • Sanofi
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Novel Oral AntiCoagulants (NOAC) Market by Type
  3. 1.2.1 Global Novel Oral AntiCoagulants (NOAC) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Direct Thrombin Inhibitors
  5. 1.2.3 Direct Factor Xa Inhibitors
  6. 1.3 Novel Oral AntiCoagulants (NOAC) Market by Application
  7. 1.3.1 Global Novel Oral AntiCoagulants (NOAC) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hemodialysis
  9. 1.3.3 Deep Vein Thrombosis (DVT)
  10. 1.3.4 Acute Coronary Syndrome
  11. 1.3.5 Pulmonary Embolism
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Novel Oral AntiCoagulants (NOAC) Market Dynamics
  1. 2.1 Novel Oral AntiCoagulants (NOAC) Industry Trends
  2. 2.2 Novel Oral AntiCoagulants (NOAC) Industry Drivers
  3. 2.3 Novel Oral AntiCoagulants (NOAC) Industry Opportunities and Challenges
  4. 2.4 Novel Oral AntiCoagulants (NOAC) Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Novel Oral AntiCoagulants (NOAC) Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Region
  3. 3.2.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Region (2021-2026)
  5. 3.2.3 Global Novel Oral AntiCoagulants (NOAC) Revenue by Region (2027-2032)
  6. 3.2.4 Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Novel Oral AntiCoagulants (NOAC) Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Novel Oral AntiCoagulants (NOAC) Sales by Region
  9. 3.4.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2021-2026)
  11. 3.4.3 Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2027-2032)
  12. 3.4.4 Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Manufacturers
  2. 4.1.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Novel Oral AntiCoagulants (NOAC) Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Manufacturers
  6. 4.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Novel Oral AntiCoagulants (NOAC) Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Novel Oral AntiCoagulants (NOAC) Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Novel Oral AntiCoagulants (NOAC) Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Novel Oral AntiCoagulants (NOAC) Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Novel Oral AntiCoagulants (NOAC) Manufacturers, Product Type & Application
  13. 4.7 Global Novel Oral AntiCoagulants (NOAC) Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Novel Oral AntiCoagulants (NOAC) Market CR5 and HHI
  16. 4.8.2 2025 Novel Oral AntiCoagulants (NOAC) Tier 1, Tier 2, and Tier 3
5 Novel Oral AntiCoagulants (NOAC) Market by Type
  1. 5.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Type
  2. 5.1.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Type
  6. 5.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2021-2032)
  9. 5.3 Global Novel Oral AntiCoagulants (NOAC) Price by Type
6 Novel Oral AntiCoagulants (NOAC) Market by Application
  1. 6.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Application
  2. 6.1.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Application
  6. 6.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2021-2032)
  9. 6.3 Global Novel Oral AntiCoagulants (NOAC) Price by Application
7 Company Profiles
  1. 7.1 Armatheon
  2. 7.1.1 Armatheon Company Information
  3. 7.1.2 Armatheon Business Overview
  4. 7.1.3 Armatheon Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Armatheon Novel Oral AntiCoagulants (NOAC) Product Portfolio
  6. 7.1.5 Armatheon Recent Developments
  7. 7.2 Aspen
  8. 7.2.1 Aspen Company Information
  9. 7.2.2 Aspen Business Overview
  10. 7.2.3 Aspen Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Aspen Novel Oral AntiCoagulants (NOAC) Product Portfolio
  12. 7.2.5 Aspen Recent Developments
  13. 7.3 Boehringer Ingelheim
  14. 7.3.1 Boehringer Ingelheim Company Information
  15. 7.3.2 Boehringer Ingelheim Business Overview
  16. 7.3.3 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product Portfolio
  18. 7.3.5 Boehringer Ingelheim Recent Developments
  19. 7.4 Bristol-Myers Squibb
  20. 7.4.1 Bristol-Myers Squibb Company Information
  21. 7.4.2 Bristol-Myers Squibb Business Overview
  22. 7.4.3 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Recent Developments
  25. 7.5 Cellceutix
  26. 7.5.1 Cellceutix Company Information
  27. 7.5.2 Cellceutix Business Overview
  28. 7.5.3 Cellceutix Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Cellceutix Novel Oral AntiCoagulants (NOAC) Product Portfolio
  30. 7.5.5 Cellceutix Recent Developments
  31. 7.6 Cosmo Pharmaceuticals
  32. 7.6.1 Cosmo Pharmaceuticals Company Information
  33. 7.6.2 Cosmo Pharmaceuticals Business Overview
  34. 7.6.3 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio
  36. 7.6.5 Cosmo Pharmaceuticals Recent Developments
  37. 7.7 CSL Behring
  38. 7.7.1 CSL Behring Company Information
  39. 7.7.2 CSL Behring Business Overview
  40. 7.7.3 CSL Behring Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 CSL Behring Novel Oral AntiCoagulants (NOAC) Product Portfolio
  42. 7.7.5 CSL Behring Recent Developments
  43. 7.8 Daiichi Sankyo
  44. 7.8.1 Daiichi Sankyo Company Information
  45. 7.8.2 Daiichi Sankyo Business Overview
  46. 7.8.3 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product Portfolio
  48. 7.8.5 Daiichi Sankyo Recent Developments
  49. 7.9 Marathon Pharmaceuticals
  50. 7.9.1 Marathon Pharmaceuticals Company Information
  51. 7.9.2 Marathon Pharmaceuticals Business Overview
  52. 7.9.3 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio
  54. 7.9.5 Marathon Pharmaceuticals Recent Developments
  55. 7.10 Ockham Biotech
  56. 7.10.1 Ockham Biotech Company Information
  57. 7.10.2 Ockham Biotech Business Overview
  58. 7.10.3 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product Portfolio
  60. 7.10.5 Ockham Biotech Recent Developments
  61. 7.11 Perosphere
  62. 7.11.1 Perosphere Company Information
  63. 7.11.2 Perosphere Business Overview
  64. 7.11.3 Perosphere Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Perosphere Novel Oral AntiCoagulants (NOAC) Product Portfolio
  66. 7.11.5 Perosphere Recent Developments
  67. 7.12 AstraZeneca
  68. 7.12.1 AstraZeneca Company Information
  69. 7.12.2 AstraZeneca Business Overview
  70. 7.12.3 AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 AstraZeneca Novel Oral AntiCoagulants (NOAC) Product Portfolio
  72. 7.12.5 AstraZeneca Recent Developments
  73. 7.13 Bayer
  74. 7.13.1 Bayer Company Information
  75. 7.13.2 Bayer Business Overview
  76. 7.13.3 Bayer Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Bayer Novel Oral AntiCoagulants (NOAC) Product Portfolio
  78. 7.13.5 Bayer Recent Developments
  79. 7.14 GSK
  80. 7.14.1 GSK Company Information
  81. 7.14.2 GSK Business Overview
  82. 7.14.3 GSK Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 GSK Novel Oral AntiCoagulants (NOAC) Product Portfolio
  84. 7.14.5 GSK Recent Developments
  85. 7.15 Johnson & Johnson
  86. 7.15.1 Johnson & Johnson Company Information
  87. 7.15.2 Johnson & Johnson Business Overview
  88. 7.15.3 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product Portfolio
  90. 7.15.5 Johnson & Johnson Recent Developments
  91. 7.16 Sanofi
  92. 7.16.1 Sanofi Company Information
  93. 7.16.2 Sanofi Business Overview
  94. 7.16.3 Sanofi Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Sanofi Novel Oral AntiCoagulants (NOAC) Product Portfolio
  96. 7.16.5 Sanofi Recent Developments
  97. 7.17 Eisai
  98. 7.17.1 Eisai Company Information
  99. 7.17.2 Eisai Business Overview
  100. 7.17.3 Eisai Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Eisai Novel Oral AntiCoagulants (NOAC) Product Portfolio
  102. 7.17.5 Eisai Recent Developments
8 North America
  1. 8.1 North America Novel Oral AntiCoagulants (NOAC) Market Size by Type
  2. 8.1.1 North America Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021-2032)
  3. 8.1.2 North America Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2032)
  4. 8.1.3 North America Novel Oral AntiCoagulants (NOAC) Price by Type (2021-2032)
  5. 8.2 North America Novel Oral AntiCoagulants (NOAC) Market Size by Application
  6. 8.2.1 North America Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021-2032)
  7. 8.2.2 North America Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2032)
  8. 8.2.3 North America Novel Oral AntiCoagulants (NOAC) Price by Application (2021-2032)
  9. 8.3 North America Novel Oral AntiCoagulants (NOAC) Market Size by Country
  10. 8.3.1 North America Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Novel Oral AntiCoagulants (NOAC) Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Novel Oral AntiCoagulants (NOAC) Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Novel Oral AntiCoagulants (NOAC) Market Size by Type
  2. 9.1.1 Europe Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021-2032)
  3. 9.1.2 Europe Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2032)
  4. 9.1.3 Europe Novel Oral AntiCoagulants (NOAC) Price by Type (2021-2032)
  5. 9.2 Europe Novel Oral AntiCoagulants (NOAC) Market Size by Application
  6. 9.2.1 Europe Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021-2032)
  7. 9.2.2 Europe Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2032)
  8. 9.2.3 Europe Novel Oral AntiCoagulants (NOAC) Price by Application (2021-2032)
  9. 9.3 Europe Novel Oral AntiCoagulants (NOAC) Market Size by Country
  10. 9.3.1 Europe Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Novel Oral AntiCoagulants (NOAC) Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Novel Oral AntiCoagulants (NOAC) Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Novel Oral AntiCoagulants (NOAC) Market Size by Type
  2. 10.1.1 China Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021-2032)
  3. 10.1.2 China Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2032)
  4. 10.1.3 China Novel Oral AntiCoagulants (NOAC) Price by Type (2021-2032)
  5. 10.2 China Novel Oral AntiCoagulants (NOAC) Market Size by Application
  6. 10.2.1 China Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021-2032)
  7. 10.2.2 China Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2032)
  8. 10.2.3 China Novel Oral AntiCoagulants (NOAC) Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Novel Oral AntiCoagulants (NOAC) Market Size by Type
  2. 11.1.1 Asia Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021-2032)
  3. 11.1.2 Asia Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2032)
  4. 11.1.3 Asia Novel Oral AntiCoagulants (NOAC) Price by Type (2021-2032)
  5. 11.2 Asia Novel Oral AntiCoagulants (NOAC) Market Size by Application
  6. 11.2.1 Asia Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021-2032)
  7. 11.2.2 Asia Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2032)
  8. 11.2.3 Asia Novel Oral AntiCoagulants (NOAC) Price by Application (2021-2032)
  9. 11.3 Asia Novel Oral AntiCoagulants (NOAC) Market Size by Country
  10. 11.3.1 Asia Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Novel Oral AntiCoagulants (NOAC) Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Novel Oral AntiCoagulants (NOAC) Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Novel Oral AntiCoagulants (NOAC) Market Size by Type
  2. 12.1.1 SAMEA Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Novel Oral AntiCoagulants (NOAC) Price by Type (2021-2032)
  5. 12.2 SAMEA Novel Oral AntiCoagulants (NOAC) Market Size by Application
  6. 12.2.1 SAMEA Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Novel Oral AntiCoagulants (NOAC) Price by Application (2021-2032)
  9. 12.3 SAMEA Novel Oral AntiCoagulants (NOAC) Market Size by Country
  10. 12.3.1 SAMEA Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Novel Oral AntiCoagulants (NOAC) Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Novel Oral AntiCoagulants (NOAC) Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Novel Oral AntiCoagulants (NOAC) Value Chain Analysis
  2. 13.1.1 Novel Oral AntiCoagulants (NOAC) Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Novel Oral AntiCoagulants (NOAC) Production Mode & Process
  6. 13.2 Novel Oral AntiCoagulants (NOAC) Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Novel Oral AntiCoagulants (NOAC) Distributors
  9. 13.2.3 Novel Oral AntiCoagulants (NOAC) Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst